/C O R R E C T I O N — Sinovac Biotech Ltd./
In the news release, “Sinovac Obtains Fifth H1N1 Vaccine Order from
Chinese Central Government,” issued earlier today by Sinovac Biotech Ltd. over
PR Newswire, we are advised by the company that the first sentence of the
second paragraph should read,” In aggregate, Sinovac has received orders of
PANFLU.1 from the Chinese government for a total 21.06 million doses, and
10.23 million doses of PANFLU.1 have been delivered to date for the Chinese
vaccination campaign,” rather than, “In aggregate, Sinovac has received orders
of PANFLU.1 from the Chinese government for a total 20.05 million doses, and
10.23 million doses of PANFLU.1 have been delivered to date for the Chinese
vaccination campaign,” as originally issued inadvertently. The complete,
corrected release follows.
Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
a leading provider of biopharmaceutical products in
that it has received its fifth purchase order for its H1N1 vaccine,
PANFLU.1(TM), from
the national purchase plan. Under this purchase order, Sinovac is required to
deliver an additional 8.57 million doses of PANFLU.1(TM) (15ug/0.5ml) to the
Chinese Central Government, of which 2.33 million doses are expected to be
delivered before
stockpiled by the government in Sinovac’s warehouse facility.
In aggregate, Sinovac has received orders of PANFLU.1 from the Chinese
government for a total 21.06 million doses, and 10.23 million doses of
PANFLU.1 have been delivered to date for the Chinese vaccination campaign. In
2009, the Company completed the expansion of its production line used to
manufacture the seasonal influenza, H1N1 and H5N1 vaccines, thereby increasing
its annual production capacity by approximately 60%.
Mr.
fifth order from the Chinese Central Government demonstrates Sinovac’s
continuing ability to complete its national H1N1 vaccine stockpiling tasks in
a timely manner. The production capacity expansion has continued to serve its
purpose in positioning Sinovac to operate even more efficiently towards our
goal of providing citizens of
vaccines.”
About Sinovac
Sinovac Biotech Ltd. is a
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac’s vaccine
products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and
B), and Anflu(R) (influenza). Panflu(R) and PANFLU.1(TM), Sinovac’s pandemic
influenza vaccine (H5N1) and H1N1 vaccine, have already been approved for
government stockpiling. Sinovac is developing vaccines for enterovirus 71,
universal pandemic influenza, Japanese encephalitis, and human rabies. Its
wholly owned subsidiary, Tangshan Yian, is conducting field trials for
independently developed inactivated animal
Safe Harbor Statement
This announcement contains forward-looking statements. These statements
are made under the “safe harbor” provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as “will,” “expects,” “anticipates,”
“future,” “intends,” “plans,” “believes,” “estimates” and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac’s beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any forward-
looking statement. Sinovac does not undertake any obligation to update any
forward-looking statement, except as required under applicable law.
For more information, please contact:
Helen G. Yang
Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x9871
Fax: +86-10-6296-6910
Email: info@sinovac.com
Investors:
Amy Glynn/Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7023/7017
Email: aglynn@theruthgroup.com
scarrington@theruthgroup.com
Media:
Janine McCargo
The Ruth Group
Tel: +1-646-536-7033
Email: jmccargo@theruthgroup.com
——
Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
a leading provider of biopharmaceutical products in
that it has received its fifth purchase order for its H1N1 vaccine,
PANFLU.1(TM), from
the national purchase plan. Under this purchase order, Sinovac is required to
deliver an additional 8.57 million doses of PANFLU.1(TM) (15ug/0.5ml) to the
Chinese Central Government, of which 2.33 million doses are expected to be
delivered before
stockpiled by the government in Sinovac’s warehouse facility.
In aggregate, Sinovac has received orders of PANFLU.1 from the Chinese
government for a total 20.05 million doses, and 10.23 million doses of
PANFLU.1 have been delivered to date for the Chinese vaccination campaign. In
2009, the Company completed the expansion of its production line used to
manufacture the seasonal influenza, H1N1 and H5N1 vaccines, thereby increasing
its annual production capacity by approximately 60%.
Mr.
fifth order from the Chinese Central Government demonstrates Sinovac’s
continuing ability to complete its national H1N1 vaccine stockpiling tasks in
a timely manner. The production capacity expansion has continued to serve its
purpose in positioning Sinovac to operate even more efficiently towards our
goal of providing citizens of
vaccines.”
About Sinovac
Sinovac Biotech Ltd. is a
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac’s vaccine
products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and
B), and Anflu(R) (influenza). Panflu(R) and PANFLU.1(TM), Sinovac’s pandemic
influenza vaccine (H5N1) and H1N1 vaccine, have already been approved for
government stockpiling. Sinovac is developing vaccines for enterovirus 71,
universal pandemic influenza, Japanese encephalitis, and human rabies. Its
wholly owned subsidiary, Tangshan Yian, is conducting field trials for
independently developed inactivated animal
Safe Harbor Statement
This announcement contains forward-looking statements. These statements
are made under the “safe harbor” provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as “will,” “expects,” “anticipates,”
“future,” “intends,” “plans,” “believes,” “estimates” and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac’s beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any forward-
looking statement. Sinovac does not undertake any obligation to update any
forward-looking statement, except as required under applicable law.
For more information, please contact:
Helen G. Yang
Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x9871
Fax: +86-10-6296-6910
Email: info@sinovac.com
Investors:
Amy Glynn/Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7023/7017
Email: aglynn@theruthgroup.com
scarrington@theruthgroup.com
Media:
Janine McCargo
The Ruth Group
Tel: +1-646-536-7033
Email: jmccargo@theruthgroup.com
SOURCE Sinovac Biotech Ltd.